Here is a list of publications that I printed out for someone possibly seeking an EIND for breast cancer to give to their doctor. I also printed out the list of links and a cover letter for contacting Cytodyn. It's not TNBC so she's not eligible for the current or upcoming trial.
Online Links to Publications
Leronlimab is associated with long-term survival in metastatic TNBC: Enhancing PD-L1 expression, ICI response, and modulates T cell exhaustion
Abstract - https://aacrjournals.org/cancerimmunolres/art...-with-long
Poster - https://d1io3yog0oux5.cloudfront.net/_976f96f...evised.pdf
Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer
Abstract - https://aacrjournals.org/clincancerres/articl...llowing-PD
Poster - https://d1io3yog0oux5.cloudfront.net/_fb000f7..._FINAL.pdf
Long Term Survival with Leronlimab Treatment in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
Poster - https://d1io3yog0oux5.cloudfront.net/_976f96f...28h%29.pdf
Leronlimab induces PD-L1 expression and is associated with long‑term survival with an ICI in PD-L1 low metastatic TNBC
Abstract (for April 19, 2026 presentation) - https://www.abstractsonline.com/pp8/#!/21436/...ation/9742
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy
Publication - https://link.springer.com/article/10.1186/s13058-021-01391-1
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
Publication - https://pdfs.semanticscholar.org/c499/b3b8f8d...32aa89.pdf
The CCL5/CCR5 Axis in Cancer Progression
Publication - https://www.mdpi.com/2072-6694/12/7/1765
====================================================
Contact Information
Website - www.cytodyn.com
Phone - 360-980-8524
Email - info@cytodyn.com
Cytodyn welcomes all requests for the use of it's drug leronlimab under the FDA's Emergency Investigational New Drug Program. The preferred method of contact by physicians or patients is through Cytodyn's email address. Cytodyn will respond with more information about the drug and the steps to take to initiate the EIND process.
Online Links to Publications
Leronlimab is associated with long-term survival in metastatic TNBC: Enhancing PD-L1 expression, ICI response, and modulates T cell exhaustion
Abstract - https://aacrjournals.org/cancerimmunolres/art...-with-long
Poster - https://d1io3yog0oux5.cloudfront.net/_976f96f...evised.pdf
Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer
Abstract - https://aacrjournals.org/clincancerres/articl...llowing-PD
Poster - https://d1io3yog0oux5.cloudfront.net/_fb000f7..._FINAL.pdf
Long Term Survival with Leronlimab Treatment in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
Poster - https://d1io3yog0oux5.cloudfront.net/_976f96f...28h%29.pdf
Leronlimab induces PD-L1 expression and is associated with long‑term survival with an ICI in PD-L1 low metastatic TNBC
Abstract (for April 19, 2026 presentation) - https://www.abstractsonline.com/pp8/#!/21436/...ation/9742
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy
Publication - https://link.springer.com/article/10.1186/s13058-021-01391-1
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
Publication - https://pdfs.semanticscholar.org/c499/b3b8f8d...32aa89.pdf
The CCL5/CCR5 Axis in Cancer Progression
Publication - https://www.mdpi.com/2072-6694/12/7/1765
====================================================
Contact Information
Website - www.cytodyn.com
Phone - 360-980-8524
Email - info@cytodyn.com
Cytodyn welcomes all requests for the use of it's drug leronlimab under the FDA's Emergency Investigational New Drug Program. The preferred method of contact by physicians or patients is through Cytodyn's email address. Cytodyn will respond with more information about the drug and the steps to take to initiate the EIND process.
39
